Companies › RECORDATI GROUP
2 active drug programs in 4 registered trials: 2 Phase 4, 2 Phase 2; Metabolic and endocrine, Cardiovascular; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Osilodrostat (LCI699) Cytochrome P450 11B1 inhibitor | CYP11B1 | Phase 4 | Hypertension; Cushing Syndrome; Mild Autonomous Cortisol Secretion (MACS) | Jul 2027 |
| Pasireotide Diaspartate Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 2 | Post-Bariatric Hypoglycemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05928390 | Pasireotide Diaspartate | Phase 2 | Post-Bariatric Hypoglycemia | Metabolic and endocrine | Oct 2026 |
| NCT03708900 | Osilodrostat (LCI699) | Phase 2 | Cushing Syndrome | Metabolic and endocrine | Jul 2027 |
| NCT07268222 | Osilodrostat (LCI699) | Phase 4 | Mild Autonomous Cortisol Secretion (MACS) | Metabolic and endocrine | Nov 2027 |
| NCT07247162 | Osilodrostat (LCI699) | Phase 4 | Hypertension | Cardiovascular | May 2028 |
Kailera Crystalys Therapeutics Vincentage Pharma Rhythm Pharmaceuticals Rare Thyroid Therapeutics International
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.